Public Profile

Daiichi Sankyo

Daiichi Sankyo Company, Limited, commonly referred to as Daiichi Sankyo, is a prominent global pharmaceutical firm headquartered in Tokyo, Japan. Founded in 1899, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative healthcare solutions. Specialising in the research, development, and manufacturing of pharmaceuticals, Daiichi Sankyo is particularly renowned for its contributions to oncology, cardiovascular, and vaccine development. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, positioning it as a leader in the pharmaceutical industry. With a rich history marked by key milestones, Daiichi Sankyo has achieved notable success, including the development of groundbreaking therapies that have transformed treatment paradigms. Its dedication to innovation and quality has solidified its reputation as a trusted name in healthcare worldwide.

DitchCarbon Score

How does Daiichi Sankyo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

36

Industry Average

Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

26

Industry Benchmark

Daiichi Sankyo's score of 36 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.

63%

Let us know if this data was useful to you

Daiichi Sankyo's reported carbon emissions

In 2023, Daiichi Sankyo reported total carbon emissions of approximately 4,602,874,000 kg CO2e globally. This includes 82,658,000 kg CO2e from Scope 1 emissions and 24,063,000 kg CO2e from Scope 2 emissions. Notably, the company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions by fiscal year 2050 for both Scope 1 and Scope 2 emissions. This long-term target reflects their commitment to sustainability and aligns with global climate goals. In Japan, Daiichi Sankyo's emissions for 2023 were approximately 63,004,000 kg CO2e for Scope 1 and 2,173,000 kg CO2e for Scope 2. The company is actively working towards reducing its carbon footprint and has made significant strides in its sustainability initiatives. Daiichi Sankyo's focus on achieving net-zero emissions by 2050 demonstrates a proactive approach to addressing climate change and reducing its environmental impact.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201220132014201520162017201820192020202120222023
Scope 1
217,257,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
304,293,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
-
-
-
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Daiichi Sankyo's primary industry is Medical, precision and optical instruments, watches and clocks (33), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Daiichi Sankyo is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Daiichi Sankyo is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Zyla Life Sciences

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Takeda

JP
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Tty Biopharm

TW
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Jazz Pharmaceuticals

GB
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Protein Sciences Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

TG Therapeutics, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers